Treatment Outcomes with Hypomethylating Agents and Venetoclax for AML in the Community Compared to an Academic Setting

被引：0
|
作者：
Jeffrey, Lantz, Jr. [1 ]
Pham, Natalie [2 ]
Jones, Caroline [3 ]
Kundu, Debamita [4 ]
McCann, Nicholas [5 ]
El Chaer, Firas [1 ]
Reed, Daniel [1 ]
Keng, Michael [1 ]
机构：
[1] Univ Virginia, Div Hematol & Oncol, Dept Med, Comprehens Canc Ctr,Med Ctr, Charlottesville, VA USA
[2] Univ Virginia, Dept Med, Med Ctr, Charlottesville, VA USA
[3] Univ Virginia, Dept Pharm, Med Ctr, Charlottesville, VA USA
[4] Univ Virginia, Div Biostat, Charlottesville, VA USA
[5] Univ Virginia, Sch Med, Charlottesville, VA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190176
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States
    Vachhani, Pankit
    Abbas, Jonathan A.
    Flahavan, Evelyn M.
    Ma, Esprit
    Xu, Tao
    Jin, Huan
    Montez, Melissa
    Huang, Weize
    Gershon, Anda
    Ku, Grace
    Flores, Brannon
    Onishi, Maika
    Bui, Cat N.
    Donnellan, William
    BLOOD, 2021, 138
  • [22] Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy
    Madarang, Ellen
    Lykon, Jillian
    Zhao, Wei
    Sekeres, Mikkael A.
    Bradley, Terrence
    Chandhok, Namrata Sonia
    Taylor, Justin
    Koru-Sengul, Tulay
    Iyer, Sunil G.
    Nanni, Jacopo
    Papayannidis, Cristina
    Miller, Ryan M.
    Kishtagari, Ashwin
    Savona, Michael R.
    Gilbert, Jason
    Pollyea, Daniel A.
    Sallman, David A.
    Al Ali, Najla
    Komrokji, Rami S.
    Watts, Justin
    BLOOD, 2022, 140 : 3306 - 3308
  • [23] Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax
    Chen, Evan C.
    Liu, Yiwen
    Harris, Courtney E.
    Winer, Eric S.
    Wadleigh, Martha
    Lane, Andrew A.
    Vedula, Rahul S.
    Lindsley, R. Coleman
    Copson, Kevin M.
    Charles, Anne
    Marty, Francisco
    Neuberg, Donna
    DeAngelo, Daniel J.
    Stone, Richard M.
    Luskin, Marlise R.
    Issa, Nicolas C.
    Garcia, Jacqueline S.
    LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1934 - 1941
  • [24] Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
    Shimony, Shai
    Garcia, Jacqueline S.
    Keating, Julia
    Chen, Evan C.
    Luskin, Marlise R.
    Stahl, Maximilian
    Neuberg, Donna S.
    Deangelo, Daniel J.
    Stone, Richard M.
    Lindsley, R. Coleman
    LEUKEMIA, 2024, 38 (07) : 1494 - 1500
  • [25] Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax
    Shimony, Shai
    Garcia, Jacqueline S.
    Keating, Julia
    Chen, Evan C.
    Luskin, Marlise R.
    Stahl, Maximilian
    Neuberg, Donna S.
    DeAngelo, Daniel J.
    Stone, Richard M.
    Lindsley, Coleman
    BLOOD, 2023, 142
  • [26] Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options
    Daniel R. Richardson
    Steven D. Green
    Matthew C. Foster
    Joshua F. Zeidner
    Current Hematologic Malignancy Reports, 2021, 16 : 97 - 111
  • [27] Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options
    Richardson, Daniel R.
    Green, Steven D.
    Foster, Matthew C.
    Zeidner, Joshua F.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2021, 16 (01) : 97 - 111
  • [28] Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia
    Kennedy, Vanessa E.
    Hui, Gavin
    Azenkot, Tali
    Gaut, Daria
    Wieduwilt, Matthew J.
    Oliai, Caspian
    Jonas, Brian A.
    Mittal, Varun
    Logan, Aaron C.
    Muffly, Lori S.
    Mannis, Gabriel N.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (06) : E191 - E194
  • [29] Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)
    Tan, Irena
    Schwede, Matthew
    Phan, Paul
    Yin, Raymond
    Zhang, Tian Y.
    Mannis, Gabriel N.
    BLOOD, 2021, 138
  • [30] Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML- a Real-World Evidence Comparison By Treatment with Hypomethylating Agents plus Ivosidenib or Venetoclax
    Smith, Douglas
    Lachowiez, Curtis A.
    Ambinder, Alexander J.
    Binder, Gary
    Angiolillo, Anne
    Potluri, Ravi
    Papademetriou, Eros
    Leblanc, Thomas W.
    BLOOD, 2024, 144 : 2855 - 2856
12345